Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
Heng LiZhangqun Ye

Abstract

Androgen-deprivation therapy has been the standard treatment for metastatic and locally advanced prostate cancer, but the majority of patients will progress to castration-resistant prostate cancer within 2-3 years. Unlike the case in breast cancer, no clinically validated biomarker has been used to predict the outcomes of androgen-deprivation therapy. To evaluate androgen-receptor splice variant-7 (AR-V7) detection in newly diagnosed advanced prostate cancer and describe the distinctive prognosis of this novel molecular subtype, this study retrospectively enrolled 168 newly diagnosed prostate cancer patients from 2003 to 2015 who received androgen-deprivation therapy. AR-V7 immunohistochemical staining was performed with a monoclonal antibody, and AR-V7 expression was determined using Immune-Reactive Score data. The association between nuclear AR-V7 expression and prognosis was determined. Multiple cause-specific Cox regression and stratified cumulative incidences were used to analyze the prognosis risk. Among the 168 patients, 32 (19%) were AR-V7-positive. Compared with the AR-V7-negative patients, the AR-V7-positive patients had significantly lower prostate-specific antigen response rates (P<0.001) to androgen-deprivation the...Continue Reading

References

Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maha HussainUNKNOWN Southwest Oncology Group Trial 9346 (INT-0162)
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Feb 10, 2009·Nature Clinical Practice. Urology·William P HarrisBruce Montgomery
Jul 21, 2010·The Journal of Clinical Investigation·Shihua SunStephen R Plymate
Sep 9, 2010·Proceedings of the National Academy of Sciences of the United States of America·Philip A WatsonCharles L Sawyers
Jun 15, 2012·European Urology·Atish D ChoudhuryTapio Visakorpi
Oct 12, 2013·CA: a Cancer Journal for Clinicians·Carol DeSantisAhmedin Jemal
Sep 4, 2014·The New England Journal of Medicine·Emmanuel S AntonarakisJun Luo
Feb 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group 3

❮ Previous
Next ❯

Citations

May 5, 2018·Advances in Anatomic Pathology·Jane Kim Nguyen, Cristina Magi-Galluzzi
Oct 20, 2018·The Journal of Clinical Investigation·Adam SharpStephen R Plymate
Sep 12, 2018·Diagnostics·Arlou Kristina AngelesHolger Sültmann
Apr 28, 2019·International Journal of Molecular Sciences·Namrata Khurana, Suresh C Sikka
Mar 7, 2020·Prostate Cancer and Prostatic Diseases·Changxue LuJun Luo
Sep 14, 2018·The World Journal of Men's Health·Kazutoshi Fujita, Norio Nonomura
Feb 1, 2021·Cancer Treatment and Research Communications·Adam G SowalskyStephen R Plymate
Jul 29, 2021·Journal of Cell Science·Fatma ÖzgünNathan A Lack
Jan 20, 2020·Urologia Internationalis·Holger Hans Herman ErbChristian Thomas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.